Skip to main content

Together we are beating cancer

Donate now

Cancer News

The latest news, analysis and opinion from Cancer Research UK

Targeted therapies

Showing 12 out of 71 results
Cancer Research UK scientists in the lab

NHS England will offer the newly-approved dabrafenib plus trametinib combination to children and young people whose gliomas are being driven by a specific genetic mutation. NHS England will offer the newly-approved dabrafenib plus trametinib combination to children and young people whose gliomas are being driven by a specific genetic mutation.

by Tim Gunn | News | 13 June 2024

13 June 2024

Two cancer researchers looking at a cell image on screen

Each cancer is as unique as the person it affects. By studying patient data, we can target our treatments to people's specific needs. Each cancer is as unique as the person it affects. By studying patient data, we can target our treatments to people's specific needs.

by Cancer Research UK | In depth | 21 November 2023

21 November 2023

A prostate cancer cell.

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

by Jacob Smith | News | 13 September 2022

13 September 2022

3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer. 3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer.

by Harry Jenkins | News | 19 January 2022

19 January 2022

Breast cancer screening

Cancer Research UK-funded scientists are using innovative techniques to understand how resistance to a targeted cancer drug is unfolding. Cancer Research UK-funded scientists are using innovative techniques to understand how resistance to a targeted cancer drug is unfolding.

by Lilly Matson | Analysis | 10 January 2022

10 January 2022

Lung cancer cell

More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence. More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence.

by Harry Jenkins | News | 1 December 2021

1 December 2021

Lung cancer cells

Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected. Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.

by Harry Jenkins | News | 11 November 2021

11 November 2021

3D visualisation of thyroid cancer

The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer. The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer.

by Harry Jenkins | News | 1 October 2021

1 October 2021